Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line sintilimab with or without chemotherapy for advanced non-small cell lung cancer guided by immune response-related markers
ChiCTR2100044514Phase 2Recruiting
- Sponsor
- Oncology Department of PLA General Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Oncology Department of PLA General Hospital. Primary endpoint: Progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100044514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044514.